asx announcements

Visit ASX website for all Opthea Limited ASX announcements

20 MAR 2017

Opthea Receives EU Regulatory Feedback for OPT-302 Program

read more >>
09 MAR 2017

Opthea Completes FDA Meeting to Inform OPT-302 Program

read more >>
21 FEB 2017

Opthea Half Year Report and Accounts

read more >>
09 JAN 2017

Opthea Corporate Presentation during JPMorgan Conference

read more >>
28 NOV 2016

Results of Meeting

read more >>
28 NOV 2016

Opthea CEO Presentation to the 2016 AGM

read more >>
28 NOV 2016

Opthea Chairman's Address to the 2016 AGM

read more >>
21 NOV 2016

Opthea Completes Patient Enrolment in Ph 1/2A wAMD Trial

read more >>
28 OCT 2016

Notice of Annual General Meeting and Proxy Form

read more >>
17 OCT 2016

Opthea receives $2.6M R&D tax incentive

read more >>
12 SEP 2016

Opthea Ph1 wAMD data presented at EURETINA 2016

read more >>
29 AUG 2016

Appendix 4G and Corporate Governance Statement 2016

read more >>
29 AUG 2016

Appendix 4E and Annual Report 2016

read more >>
08 AUG 2016

Opthea to Present at Ophthalmology Innovation Summit in US

read more >>
26 JUL 2016

Opthea Reports Positive Data from Wet AMD Clinical Trial

read more >>
25 JUL 2016

Opthea to Host Conference Call Update on Wet AMD Trial

read more >>
18 MAY 2016

Appendix 3B

read more >>
16 MAY 2016

Change in Substantial Holding for ANP

read more >>
05 MAY 2016

Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD

read more >>
21 APR 2016

Opthea Phase 1 wet AMD Clinical Trial with OPT-302 Meets Primary Safety Objective

read more >>
07 APR 2016

Change of Director's Interest Notice_GK

read more >>
07 APR 2016

Change of Director's Interest Notice_MS

read more >>
07 APR 2016

Change of Director's Interest Notice_MB

read more >>
30 MAR 2016

Opthea Completes Patient Enrolment for OPT-302 Phase 1 wet AMD Trial

read more >>
07 MAR 2016

Results of the Extraordinary General Meeting

read more >>
07 MAR 2016

CEO's Address to EGM

read more >>
07 MAR 2016

Chairman's Address to EGM

read more >>
26 FEB 2016

Half-year Report and Accounts

read more >>
05 FEB 2016

Notice of Extraordinary General Meeting/Proxy Form

read more >>
30 DEC 2015

Becoming a Substantial Holder

read more >>
11 DEC 2015

Circadian Technologies Changes Name to Opthea

read more >>
02 DEC 2015

Circadian Receives $3M R&D Tax Incentive

read more >>
30 NOV 2015

Circadian Board Changes and Renewal

read more >>
30 NOV 2015

Results of the Annual General Meeting

read more >>
30 NOV 2015

CEO Presentation for the Annual General Meeting

read more >>
30 NOV 2015

Chairman’s address to the Annual General Meeting

read more >>
13 nov 2015

Circadian/Opthea presentation at OIS 2015

read more >>
10 nov 2015

Circadian to Present at US Ophthalmology Innovation Summit

read more >>
04 Nov 2015

Notice of 2015 Annual General Meeting

read more >>
23 Oct 2015

Circadian to regain VEGFR-3 intellectual property license

read more >>
09 Jul 2015

Circadian Corporate Presentation - July 2015

read more >>
01 Jul 2015

Circadian Commences Wet AMD OPT-302 Clinical Trial

read more >>
15 Jun 2015

Circadian receives IND approval from FDA to initiate clinical trial of OPT-302 for wet AMD patients

read more >>
02 Jun 2015

Circadian's Partner Eli Lilly Presents IMC-3C5 Data at ASCO

read more >>
07 May 2015

OPT-302 Data Presented at Major Ophthalmology Conferences

read more >>
07 May 2015

ARVO 2015 Conference: OPT-302 in wet AMD

read more >>
16 Apr 2015

Circadian Shareholder Newsletter April 2015

read more >>
14 Apr 2015

World Congress on Angiogenesis 2015: Poster

read more >>
27 Feb 2015

Circadian Half Year Report and Accounts

read more >>
15 Feb 2015

Circadian Investor Presentation - February 2015

read more >>
13 Feb 2015

Bioshares - Circadian Briefing Report

read more >>
05 Dec 2014

Circadian Announces Formation of Clinical Advisory Board

read more >>
26 Nov 2014

Completion of Placement and Appendix 3B

read more >>
18 Nov 2014

Results of 2014 Annual General Meeting

read more >>
18 Nov 2014

CEO's presentation to Annual General Meeting

read more >>
18 Nov 2014

Chairman's Address to Annual General Meeting: Nov 18 2014

read more >>
18 Nov 2014

CEO Address: Annual General Meeting: Nov 18 2014

read more >>
18 Nov 2014

Chairman's address to Annual General Meeting

read more >>
06 Nov 2014

Completion of Rights Issue

read more >>
17 Oct 2014

Circadian Annual General Meeting 2014

read more >>
10 Oct 2014

Circadian Letter to Shareholders

read more >>
10 Oct 2014

Circadian Capital Raising Prospectus

read more >>
06 Oct 2014

CIR Appendix 3B

read more >>
06 Oct 2014

Circadian Investment Presentation

read more >>
06 Oct 2014

Circadian Investor Presentation - Oct 6 2014

read more >>
06 Oct 2014

ASX Funding Announcement

read more >>
01 Oct 2014

Trading Halt

read more >>
30 Sep 2014

Circadian Allowed Key Patent for VEGFR-3 Traps in the United States

read more >>
29 Aug 2014

Preliminary Final Report

read more >>
23 Jun 2014

Opthea Awarded Grant for OPT-302 Manufacture

read more >>
03 Jun 2014

Poster Presentation at ASCO

read more >>
02 Jun 2014

Circadian's VGX-100 Well Tolerated in Phase 1 Clinical Trial

read more >>
19 May 2014

Circadian Appoints CFO and Company Secretary

read more >>
15 May 2014

VGX-100 Phase 1 Study Selected for Presentation at ASCO 2014

read more >>
12 May 2014

Opthea Completes Pre-IND Meeting with FDA

read more >>
07 May 2014

Poster Presentation at ARVO

read more >>
06 May 2014

VEGF-C blockade with OPT-302 reduces established wet AMD lesions in the mouse

read more >>
29 Apr 2014

CEO Terms of Employment

read more >>
21 Feb 2014

Half Year Report & Accounts

read more >>
21 Feb 2014

Circadian Appoints CEO and Managing Director

read more >>
14 Jan 2014

Opthea signs cell line commercial license agreement with Selexis

read more >>
10 Dec 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
06 Dec 2013

Appendix 3X - Initial Director’s Interest Notice

read more >>
03 Dec 2013

Circadian CEO and Board Changes

read more >>
29 Nov 2013

Results of Annual General Meeting

read more >>
29 Nov 2013

CEOs Address To Annual General Meeting

read more >>
29 Nov 2013

Chairmans Address To Annual General Meeting

read more >>
29 Nov 2013

Appendix 3Z - Final Directors Interest Notice

read more >>
29 Nov 2013

Director Resignation

read more >>
27 Nov 2013

Phase 1b oncology trial completed

read more >>
15 Nov 2013

Federal Government R&D Tax Incentive - Circadian To Receive Over $2.5m

read more >>
04 Nov 2013

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

read more >>
30 Oct 2013

Opthea Signs Manufacturing Agreement for Lead Product

read more >>
28 Oct 2013

Annual Report / Notice of AGM and Proxy

read more >>
17 Oct 2013

Phase 1a clinical oncology trial with VGX-100 update

read more >>
01 Oct 2013

Revised AGM details

read more >>
11 Sep 2013

Analyst Investment Report on Circadian Website

read more >>
10 Sep 2013

New Company Secretary

read more >>
28 Aug 2013

Open Briefing

read more >>
28 Aug 2013

2012/13 Preliminary Annual Results

read more >>
15 Jul 2013

Circadian moves to new South Yarra office

read more >>
15 Jul 2013

The FDA has taken the first step in approving VEGF-D diagnostics as a test to monitor LAM

read more >>
02 Jul 2013

FDA grants humanitarian use device designation to VEGF-D kit

read more >>
17 Jun 2013

US Patent Granted Covering use of VEGFR-3

read more >>
04 Jun 2013

VGX-100 Phase 1 Oncology Trial Presented at ASCO 2013

read more >>
04 Jun 2013

VGX-100 Poster Presentation at ASCO

read more >>
27 May 2013

Change of Director’s Interest Notice

read more >>
24 May 2013

Open Briefing: VGX-300 Potential in AMD

read more >>
23 May 2013

Change of Director’s Interest Notice

read more >>
20 May 2013

Change of Director’s Interest Notice

read more >>
17 May 2013

Progress of VGX-100 Phase 1 trial to be presented at ASCO

read more >>
09 May 2013

VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)

read more >>
08 Mar 2013

Circadian grants world-wide licence to Santa Cruz Biotechnology Inc

read more >>
06 Mar 2013

Edison Research publishes updated analysis on Circadian. Values the company at $1.93/share

read more >>
27 Feb 2013

Circadian commences worldwide marketing & sales of unique VEGF-C & VEGF-D products as research reagents

read more >>
25 Feb 2013

Open Briefing: Interview with CEO & MD Robert Klupacs on H1 Results & Outlook

read more >>
22 Feb 2013

Appointment of CFO and Company Secretary

read more >>
20 Feb 2013

Resignation of CFO and Company Secretary

read more >>
18 Feb 2013

Half Year Report & Accounts

read more >>
07 Feb 2013

R&D Tax Incentive - Circadian Receives $1.3m

read more >>
04 Feb 2013

VGX-100 Phase 1 Clinical Trial Program Update

read more >>
10 Jan 2013

Company Presentation at JP Morgan Biotech Showcase

read more >>
17 Dec 2012

Change of Director’s Interest Notice

read more >>
11 Dec 2012

Open Briefing interview with MD & CEO Robert Klupacs

read more >>
21 Nov 2012

Change of Director's Interest Notice

read more >>
21 Nov 2012

Appendix 3B

read more >>
20 Nov 2012

Results of Annual General Meeting 20 November 2012

read more >>
20 Nov 2012

CEO AGM Presentation to shareholders

read more >>
20 Nov 2012

Chairman's Address to Shareholders

read more >>
20 Nov 2012

CEO AGM Presentation to Shareholders

read more >>
15 Nov 2012

Circadian grants world-wide licence to Bio-Rad to market research products

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
08 Nov 2012

VGX-100 Poster Presentation at EORTC

read more >>
07 Nov 2012

VGX-100 Top 10 Oncology Candidate Windhover Conference

read more >>
02 Nov 2012

AusBiotech Presentation Company Update

read more >>
22 Oct 2012

Annual Report / Notice of AGM and Proxy

read more >>
02 Oct 2012

Dr Errol Malta – Resignation as Director

read more >>
24 Sep 2012

Open Briefing - FY2012 Results and Outlook

read more >>
24 Aug 2012

Appendix 3B

read more >>
24 Aug 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
23 Aug 2012

Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012

read more >>
17 Jul 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
12 Jul 2012

Change of Director’s Interest Notice

read more >>
10 Jul 2012

Change of Director’s Interest Notice

read more >>
09 Jul 2012

Alpha Securities Analyst Investment Research Report Available on Circadian Website

read more >>
07 Jul 2012

Bio 2012 - Building a Diagnostics Franchise

read more >>
27 Jun 2012

Commercial Launch of CUP Test

read more >>
22 Jun 2012

Appendix 3B

read more >>
22 Jun 2012

Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

read more >>
12 Jun 2012

Circadian makes $1M Share Placement

read more >>
12 Jun 2012

Reinstatement to Official Quotation

read more >>
07 Jun 2012

Suspension Confirm

read more >>
07 Jun 2012

Suspension Request

read more >>
05 Jun 2012

Request for Trading Halt

read more >>
01 Jun 2012

Updated Corporate Presentation

read more >>
16 May 2012

Appendix 3B

read more >>
27 Apr 2012

Notice of Ceasing to be a Substantial Holder

read more >>
02 Apr 2012

Change of Director’s Interest Notice

read more >>
29 Mar 2012

Update to Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
15 Mar 2012

Analyst Investment Research Report Available on Circadian Website

read more >>
09 Mar 2012

Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test

read more >>
09 Mar 2012

Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of Unknown Primary

read more >>
20 Feb 2012

Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook

read more >>
16 Feb 2012

Half-Year Financial Report & Operational Achievements

read more >>
30 Jan 2012

VGX-100 identified as potential new therapy for improving corneal graft survival

read more >>
12 Jan 2012

CEO Presentation at Biotech Showcase San Francisco

read more >>
09 Jan 2012

Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients

read more >>
21 Dec 2011

Change of Director’s Interest Notice

read more >>
19 Dec 2011

Finance News Network Interview with CEO Available on Circadian Website

read more >>
13 Dec 2011

Change of Director’s Interest Notice

read more >>
25 Nov 2011

Final Director’s Interest Notice

read more >>
24 Nov 2011

Results of Annual General Meeting 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Annual General Meeting Presentation 24 November 2011

read more >>
24 Nov 2011

Chairman's Address to Annual General Meeting 24 November 2011

read more >>
15 Nov 2011

Open Briefing with CEO & MD Robert Klupacs: CEO on IND status for VGX-100

read more >>
31 Oct 2011

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors

read more >>
25 Oct 2011

Change of Director's Interest Notice

read more >>
24 Oct 2011

Notice of Annual General Meeting and Explanatory Memorandum

read more >>
20 Oct 2011

Change of Director's Interest Notice

read more >>
18 Oct 2011

Final Director's Interest Notice

read more >>
11 Oct 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
11 Oct 2011

Biopartnering Europe Presentation

read more >>
10 Oct 2011

Healthscope commences clinical validation study of Circadian's Cancer Diagnostic

read more >>
03 Oct 2011

Retirements from Circadian Board of Directors

read more >>
30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

read more >>
15 Sep 2011

Open Briefing with CEO & MD Robert Klupacs: FY12 Outlook and VGX-100 Progress

read more >>
13 Sep 2011

VGX-100 identified as potential new therapy for Dry Eye Disease

read more >>
12 Sep 2011

Circadian makes key appointment in clinical trials management

read more >>
11 Sep 2011

VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling

read more >>
09 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Change of Director's Interest Notice

read more >>
07 Sep 2011

Circadian Corporate Presentation - Septemeber 2011

read more >>
06 Sep 2011

Change of Director's Interest Notice

read more >>
31 Aug 2011

Change in Substantial Holding for Optiscan Imaging Limited - Update

read more >>
31 Aug 2011

Change of Director's Interest Notice

read more >>
30 Aug 2011

Change of Director's Interest Notice

read more >>
24 Aug 2011

Preliminary Final Report Appendix 4E Financial Year Ended 30 June 2011

read more >>
25 Jul 2011

Change of Director's Interest Notice

read more >>
18 Jul 2011

Change of Directors Interest Notice

read more >>
14 Jul 2011

Open Briefing with CEO & MD Robert Klupacs

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
16 Jun 2011

Circadian provides market update on clinical development plans for VGX-100 in oncology and eye disease indications

read more >>
14 Jun 2011

Circadian launches Level 1 ADR program and OTCQX Quotation in US

read more >>
10 Jun 2011

Substantial Holding Notice for Antisense Therapeutics Limited

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
07 Jun 2011

VEGF-C and VEGF-D identified as biomarkers for Avastin resistance in colorectal cancer patients

read more >>
30 May 2011

Analyst Investment Research Reports Available on Circadian Website

read more >>
18 Apr 2011

Circadian Technologies (Small Cap Showcase 2011) - Robert Klupacs Presentation

read more >>
07 Apr 2011

Open Briefing with CEO & MD Robert Klupacs on First Phase I Clinical Trial of IMC - 3C5

read more >>
06 Apr 2011

Circadian's VGX-100 Inhibits Tumour Growth in Models of Lung, Ovarian and Prostate Cancer

read more >>
06 Apr 2011

Circadian's partner ImClone Systems commences first Phase 1 clinical trial of VEGFR-3 antibody IMC-3C5

read more >>
02 Apr 2011

The novel therapeutic monoclonal antibody VGX-100 neutralises VEGF-C and inhibits tumor growth and metastasis in subcutaneous and orthotopic models of human cancer

read more >>
22 Mar 2011

New issue announcement, application for quotation of additional securities and agreement

read more >>
15 Feb 2011

31 December 2010 Half-Year Financial Report & Operational Achievements

read more >>
14 Feb 2011

Finance News Network Interview with Circadian CEO Robert Klupacs

read more >>
02 Feb 2011

Circadian Launches First Diagnostic for LAM Lung Disease with U.S. Partner

read more >>
17 Jan 2011

VEGF-D Licence Agreement Open Briefing

read more >>
13 Jan 2011

Chugai Pharmaceutical of Japan Grants Circadian Worldwide Licence to its VEGF-D Intellectual Property Estate

read more >>
11 Jan 2011

2011 Biotech Showcase

read more >>